Odetiglucan

DRUG3 trials

Sponsors

HiberCell, Inc., Abramson Cancer Center at Penn Medicine, University of Pennsylvania

Conditions

Colorectal Adenocarcinoma Metastatic in the LiverMetastatic Pancreatic AdenocarcinomaPancreatic Ductal Adenocarcinoma

Phase 1

A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

TerminatedNCT05484011

HiberCell, Inc.Metastatic Pancreatic Adenocarcinoma

Start: 2022-12-15End: 2024-03-04Updated: 2024-04-10

Phase 2

Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma

RecruitingNCT07082439

Abramson Cancer Center at Penn MedicineColorectal Adenocarcinoma Metastatic in the Liver

Start: 2025-09-10End: 2029-09-30Target: 27Updated: 2025-09-22

Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer

RecruitingNCT07199764

University of PennsylvaniaPancreatic Ductal Adenocarcinoma

Start: 2025-11-25End: 2028-12-01Target: 100Updated: 2026-06-10

Related Papers

Phase II trial of pembrolizumab in combination with odetiglucan for patients with metastatic colorectal adenocarcinoma with liver-predominant disease.

Journal of Clinical Oncology2026-05-28